Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 145, Issue 2, 2009, Pages 195-199

  Erdemoglu, Evrim ^a   Güney, Mehmet ^a   Giray, Seren Gülşen ^b   Take, Gülnur ^b   Mungan, Tamer ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Endometrial hyperplasia; Estradiol; Mammalian target of rapamycin; Metformin; S6K1; Tamoxifen

Indexed keywords

CYCLINE; ESTRADIOL; ESTRAFEM; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; S6 KINASE; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

EID: 67650088379     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.04.034     Document Type: Article

References (23)

1. Tsang C.K., Qi H., Liu L.F., and Zheng X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12 (2007) 112-124
2. Inoki K., Ouyang H., Li Y., and Guan K.L. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69 (2005) 79
3. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 (2004) 893-900
4. Tsang C.K., and Zheng X.F. Control of ribosome biogenesis by target of rapamycin (TOR). Recent Res Dev Mol Cell Biol 5 (2004) 135-147
5. Shintani T., and Klionsky D.J. Autophagy in health and disease: a doubleedged sword. Science 306 (2004) 990-995
6. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 26 (2003) 577-590
7. Schimmack G., Defronzo R.A., and Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8 (2006) 591-602
8. Algire C., Zakikhani M., Blouin M.J., Shuai J.H., and Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15 (2008) 833-839
9. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 327 (2003) 951-953
10. Palomba S., Russo T., Orio F., et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 21 (2006) 457-465
11. Fong C.J., Burgoon L.D., Williams K.J., Forgacs A.L., and Zacharewski T.R. Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mouse. BMC Genomics 7 (2007) 151
12. Stygar D., Muravitskaya N., Eriksson B., Eriksson H., and Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 7 1 (2003) 40
13. Choi Y.H., Kim S.G., and Lee M.G. Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95 (2006) 2543-2552
14. Mutter G.L., Zaino R.J., Baak J.P., Bentley R.C., and Robboy S.J. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol. 26 (2007) 103-114
15. Milam M.R., Celestino J., Wu W., et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 196 (2007) 247.e1-247.e5
16. Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten ± mouse. Genes Dev 15 20 (2006) 1569-1574
17. Prasad M., Wang H., Douglas W., Barakat R.R., and Ellenson L.H. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol 96 (2005) 25-31
18. Ci{dotless}rpan T., Terek M.C., Ulukus M., Ulukus E.C., Akman L., and Kanit L. Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated rats. Int J Gynecol Cancer 18 (2008) 141-145
19. Treeck O., Wackwitz B., Haus U., and Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102 (2006) 292-299
20. Zhou C., Gehrig P.A., Whang Y.E., and Boggess J.F. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2 (2003) 789-795
21. Awada A., Cardoso F., Fontaine C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44 (2008) 84-91
22. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., and Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67 (2007) 10804-10812
23. Ben Sahra I.B., Laurent K., Loubat A., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008)